瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06938 瑞博生物-B

未开盘 09-08 16:08:34

58.100

+1.250

+2.20%

最高59.200	最低56.000	成交量52.48万
今开56.000	昨收56.850	日振幅5.63%
总市值98.77亿	流通市值98.77亿	总股本1.70亿
成交额3,021万	换手率0.31%	流通股本1.70亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"瑞博生物-B","latestPrice":58.1,"timestamp":1788854914838,"preClose":56.85,"halted":0,"volume":524800,"delay":0,"changeRate":0.021987686895338608,"floatShares":170000000,"shares":170000000,"eps":-2.100221,"marketStatus":"未开盘","change":1.25,"latestTime":"09-08 16:08:34","open":56,"high":59.2,"low":56,"amount":30209880,"amplitude":0.056288,"askPrice":58.3,"askSize":600,"bidPrice":58.05,"bidSize":600,"shortable":0,"etf":0,"ttmEps":-1.149,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788917400000},"marketStatusCode":0,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":56.85,"openAndCloseTimeList":[[1788831000000,1788840000000],[1788843600000,1788854400000]],"volumeRatio":0.7736321173700079,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06938","defaultTab":"news","newsList":[{"id":"1134573401","title":"瑞博生物-B：9月8日回购1.66万股，耗资约95.87万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134573401","media":"公告速递","labels":["shareholding","SGX"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134573401?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:45","pubTimestamp":1788867955,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年9月8日发布翌日披露报表。公司于当日通过香港联交所场内回购股份1.66万股，占回购前已发行股本的约0.0098%。本次回购每股价格为57.75港元，总耗资约95.87万港元。回购后，公司已发行股本由169,985,510股减少至169,968,910股，同时库藏股数增加至586,000股，总股本维持在170,554,910股。本次回购已获得公司董事会授权，并符合相关上市规则及法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B：9月8日回购1.66万股，耗资约95.87万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665272123","title":"瑞博生物-B(06938)9月8日斥资95.87万港元回购1.66万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665272123","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665272123?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:44","pubTimestamp":1788867853,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)发布公告，于2026年9月8日斥资95.87万港元回购1.66万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493506.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665941513","title":"招商证券国际：维持瑞博生物(06938.HK)“增持”评级 目标价105港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665941513","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665941513?lang=zh_cn&edition=full","pubTime":"2026-09-07 13:40","pubTimestamp":1788759653,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06099","BK1147","BK1564","06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665996933","title":"瑞博生物-B(06938.HK)获纳入恒生综合指数成份股及获调入港股通股票名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2665996933","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665996933?lang=zh_cn&edition=full","pubTime":"2026-09-07 12:30","pubTimestamp":1788755409,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06938","HSCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665944399","title":"双重纳入落地：瑞博生物获纳入恒生综合指数、沪港通及深港通标的证券","url":"https://stock-news.laohu8.com/highlight/detail?id=2665944399","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665944399?lang=zh_cn&edition=full","pubTime":"2026-09-07 12:25","pubTimestamp":1788755100,"startTime":"0","endTime":"0","summary":"瑞博生物（06938）发布公告，宣布其股份已被纳入恒生综合指数成份股，同时也被纳入沪港通及深港通南向交易的标的证券名单，自2026年9月7日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866531735.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866531735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HSCI","BK1161","06938","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108696273","title":"瑞博生物-B（06938）将于2026年9月7日纳入恒生综合指数及港股通","url":"https://stock-news.laohu8.com/highlight/detail?id=1108696273","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108696273?lang=zh_cn&edition=full","pubTime":"2026-09-07 12:16","pubTimestamp":1788754560,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司（06938，瑞博生物-B）9月7日发布自愿公告称，根据恒生指数有限公司公告，公司股份已被纳入恒生综合指数成份股，并同步调入沪港通及深港通南向交易的港股通证券名单，生效日期同为2026年9月7日。\n公司表示，进入恒生综合指数及港股通标的范围，标志着其在资本市场发展历程中的重要节点，有助于提升股份流动性、拓宽投资者基础并优化股东结构。\n截至公告日期，公司董事会成员包括执行董事梁子才博士、甘黎明博士及张鸿雁博士；非执行董事戚飞博士、李东方先生及李宇辉先生；独立非执行董事宇学峰博士、马朝松先生及王瑞平先生。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119054073","title":"瑞博生物-B更新2026年8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1119054073","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119054073?lang=zh_cn&edition=full","pubTime":"2026-09-04 18:15","pubTimestamp":1788516947,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年9月4日发布截至2026年8月31日止的股份变动月报表。根据公告，瑞博生物-B本月法定注册股本维持在人民币170,554,910元，未发生增减变动。本月未进行任何新发行、购回或注销股份活动，公司满足相关公众持股量要求。在期权与股权激励方面，瑞博生物-B当前有上市前股份期权计划2,113,987份，行使价格为每股人民币3.70元，最早归属日期为2028年1月9日。上述公告由联席公司秘书张甦于2026年9月4日签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664823893","title":"瑞博生物-B早盘涨逾4% 中期净利润为0.23亿元同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2664823893","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664823893?lang=zh_cn&edition=full","pubTime":"2026-09-02 11:05","pubTimestamp":1788318300,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端瑞博生物-B（06938）盘中涨近5%，截至发稿，股价上涨3.73%，现报62.60港元，成交额1107.78万港元。近日，瑞博生物-B披露2026年中期业绩，公司实现收入人民币4.2亿元，同比增长304%；期内净利润为人民币0.23亿元，同比实现扭亏为盈，期末现金及现金等价物为人民币22.4亿元。业绩改善主要得益于全球合作项目相关许可收入的确认及合作里程碑的持续推进。与此同时，公司继续保持对核心临床管线及创新递送平台的研发投入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-02/doc-iniqkzma1367838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664987058","title":"港股异动 | 瑞博生物-B(06938.HK)涨近5% 中期业绩实现盈利且持续改善 肝外技术有望引领下一代蓝海","url":"https://stock-news.laohu8.com/highlight/detail?id=2664987058","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664987058?lang=zh_cn&edition=full","pubTime":"2026-09-02 10:51","pubTimestamp":1788317460,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664860319","title":"中金：维持瑞博生物-B(06938.HK)跑赢行业评级 目标价90港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664860319","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664860319?lang=zh_cn&edition=full","pubTime":"2026-09-02 09:12","pubTimestamp":1788311552,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662032938","title":"瑞博生物-B(06938) 2026年中期业绩：全球合作推动收入增长，核心管线与平台价值持续兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2662032938","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662032938?lang=zh_cn&edition=full","pubTime":"2026-08-28 08:44","pubTimestamp":1787877873,"startTime":"0","endTime":"0","summary":"8月27日，瑞博生物-B 2026年中期业绩正式出炉。业绩改善主要得益于全球合作项目相关许可收入的确认及合作里程碑的持续推进。与此同时，公司继续保持对核心临床管线及创新递送平台的研发投入。实际上，上述只是瑞博生物创新平台价值兑现的一个缩影。8月21日，恒生指数系列季检结果公布，瑞博生物正式获纳入恒生综合指数成分股，后续将符合沪港通及深港通下的港股通股票的调入标准，今年9月7日起正式生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487686.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662701320","title":"瑞博生物-B(06938.HK)发布中期业绩，归母利润2030.1万元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2662701320","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662701320?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:17","pubTimestamp":1787829432,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106632009","title":"瑞博生物-B 2026年上半年财报：营收4.20亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106632009","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106632009?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:16","pubTimestamp":1787829410,"startTime":"0","endTime":"0","summary":"瑞博生物-B发布2026年上半年财报，收入为人民币4.20亿元，同比增长304.3%。报告期内毛利约人民币4.01亿元，同比增长312.2%，毛利率由上年同期的93.7%提升至95.5%。销售成本由人民币0.07亿元增长至人民币0.19亿元。研发投入为人民币1.98亿元，同比增长53.0%，主要由于核心研发管线推进至后期临床阶段及更多候选产品持续研发；行政开支为人民币0.63亿元，同比增长20.9%，部分源自上市相关活动所需的专业和咨询服务费增加。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"瑞博生物-B 2026年上半年财报：营收4.20亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661247006","title":"港股异动 | 瑞博生物-B(06938)涨超9% 获纳入恒生综指有望入通 上半年收入最高预增3.2倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2661247006","media":"智通财经","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661247006?lang=zh_cn&edition=full","pubTime":"2026-08-24 11:28","pubTimestamp":1787542130,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞博生物-B涨超9%，截至发稿，涨8.9%，报58.15港元，成交额3203.51万港元。消息面上，恒生指数公司于8月21日公布了半年度指数调整结果，其中瑞博生物获纳入恒生综合指数。变动将于9月4日收市后实施并于9月7日起生效，届时沪深交易所会相应调整港股通可投资标的范围。本次纳入恒生综合指数后，公司股票预计将同步符合港股通可投资标的资格。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","06938","VXUS","BK1161","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661262113","title":"瑞博生物-B(06938.HK)获纳入恒生综合指数 有望成为港股通标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2661262113","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661262113?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:51","pubTimestamp":1787309471,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06938","HSCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164800741","title":"瑞博生物-B（06938）拟于8月27日审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1164800741","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164800741?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:51","pubTimestamp":1786956702,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司（06938）17日公告称，公司董事会已排定于2026年8月27日（星期四）召开会议，主要议程包括：一、审议并批准本集团截至2026年6月30日止六个月的中期业绩及其发布；二、研究及考虑是否派发2026年中期股息（如有）；三、处理其他相关事项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196918869","title":"瑞博生物-B 7月股份变动月报：回购56.94万股并持作库存","url":"https://stock-news.laohu8.com/highlight/detail?id=1196918869","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196918869?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:16","pubTimestamp":1786007793,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年8月6日披露2026年7月股份变动月报表，报告期截止至2026年7月31日。报告期内，公司法定/注册股本保持人民币170,554,910元，已发行股份总数维持170,554,910股。此外，公司在上市前授出的2,113,987份股份期权仍未行使，每股行使价为人民币3.70元，因最早归属日期为2028年1月9日，报告期内无新增发行或行权情况。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656469589","title":"港股异动丨瑞博生物-B(06938.HK)盘中涨近4% 预期上半年实现收入同比增长至少约200%至320%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656469589","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656469589?lang=zh_cn&edition=full","pubTime":"2026-08-04 11:06","pubTimestamp":1785812793,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656933395","title":"险资投资策略大转向：战配、基石类升温 举牌节奏放缓","url":"https://stock-news.laohu8.com/highlight/detail?id=2656933395","media":"中国经营网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656933395?lang=zh_cn&edition=full","pubTime":"2026-08-01 02:10","pubTimestamp":1785521411,"startTime":"0","endTime":"0","summary":"中经记者樊红敏北京报道险资在资本市场的布局策略正在发生变化。一方面，险资参与上市公司IPO战略配售、基石投资的热度正在上升。7月27日，长鑫科技（688825.SH）正式登陆科创板，人保财险、中国人寿（601628.SH）、中邮人寿保、泰康人寿4家保险机构分别获配1154.73万股，对应认购金额均约1亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608013828783662.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608013828783662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00068","NBDS","301666","601628","FRHC","TECY","03986","LU1770034418.SGD","BK1521","CWC","301680","001248","LU0210526637.USD","VXUS","LU1720050803.USD","BK0175","LU1880383440.USD","LU1211504680.USD","IE0008368742.USD","600009","688825","KCAI","06880","02476","FWD","LU0117841782.USD","06938","03661","688005","06082","KCE","REDS","IPO","LU0327786744.USD","00501","03143","LU0880133367.SGD","LU0417516738.SGD","01989","03968","000958","00100","688795","IPOS","001399","301085","601112","02513","01288","06809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105332142","title":"瑞博生物-B预计上半年收入达3.11亿至4.36亿元 同比增约200%至320%","url":"https://stock-news.laohu8.com/highlight/detail?id=1105332142","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105332142?lang=zh_cn&edition=full","pubTime":"2026-07-29 18:21","pubTimestamp":1785320504,"startTime":"0","endTime":"0","summary":"2026年7月29日，瑞博生物-B发布正面财务信息预告，根据董事会对未經审计综合管理账目的初步评估，公司预计截至2026年6月30日止六个月的收入将在3.11亿元至4.36亿元之间，同比增幅约200%至320%。\\n\\n上述财务数据基于内部初步评估，尚未经过瑞博生物-B核数师或董事会审计委员会审核，最终数据将在公司预计于2026年8月底前发布的中期业绩公告中披露。\\n\\n公司提醒投资者在买卖其证券时保持审慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ribolia.com","stockEarnings":[{"period":"1week","weight":-0.0373},{"period":"1month","weight":0.112},{"period":"3month","weight":0.1795},{"period":"6month","weight":0.0184},{"period":"1year","weight":0.0022},{"period":"ytd","weight":0.0022}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":-0.0137},{"period":"3month","weight":0.0373},{"period":"6month","weight":-0.0155},{"period":"1year","weight":-0.0124},{"period":"ytd","weight":-0.0122}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"苏州瑞博生物技术股份有限公司是一家主要从事小核酸药物研究和开发，尤其专注于小干扰核酸（siRNA）疗法的中国公司。该公司主要从事小核酸药物的创新，专注于心血管、代谢类、肾脏和肝病以及其他治疗领域。该公司的药物管线包括RBD4059、RBD5044、RBD7022、RBD7007、RBD2080、RBD1119、RBD1016等。该公司主要在中国国内市场开展业务。","exchange":"SEHK","name":"瑞博生物-B","nameEN":"RIBOLIFE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供瑞博生物-B(06938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"瑞博生物-B,06938,瑞博生物-B股票,瑞博生物-B股票老虎,瑞博生物-B股票老虎国际,瑞博生物-B行情,瑞博生物-B股票行情,瑞博生物-B股价,瑞博生物-B股市,瑞博生物-B股票价格,瑞博生物-B股票交易,瑞博生物-B股票购买,瑞博生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供瑞博生物-B(06938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}